Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Type 1 Diabetes in Pregnancy: A Review of Complications and Management

Author(s): Farah Jaffar, Kate Laycock and Mohammed S.B. Huda*

Volume 18, Issue 7, 2022

Published on: 14 January, 2022

Article ID: e051121197761 Pages: 15

DOI: 10.2174/1573399818666211105124829

Price: $65

Abstract

Background: Pre-gestational diabetes can pose significant risk to the mother and infant, thus requiring careful counselling and management. Since Saint Vincent’s declaration in 1989, adverse maternal and fetal outcomes, such as preeclampsia, perinatal mortality, congenital anomalies, and macrosomia, continue to be associated with type 1 diabetes. Although pregnancy is not considered an independent risk factor for the development of new onset microvascular complications, it is known to exacerbate pre-existing microvascular disease. Strict glycaemic control is the optimal management for pre-existing type 1 diabetes in pregnancy, as raised HbA1C is associated with increased risk of maternal and fetal complications. More recently, time in range on Continuous Glucose Monitoring glucose profiles has emerged as another useful evidence-based marker of fetal outcomes.

Objectives: This review summarises the complications associated with pre-gestational type 1 diabetes, appropriate evidence-based management, including preparing for pregnancy, intrapartum and postpartum care.

Methods: A structured search of the PubMed and Cochrane databases was conducted. Peer-reviewed articles about complications and management guidelines on pre-gestational type 1 diabetes were selected and critically appraised.

Results: One hundred and twenty-three manuscripts were referenced and appraised in this review, and international guidelines were summarised.

Conclusion: This review provides a comprehensive overview of the recurring themes in the literature pertaining to type 1 diabetes in pregnancy: maternal and fetal complications, microvascular disease progression, and an overview of current guideline-specific management.

Keywords: Pre-gestational diabetes, pre-existing diabetes, type 1 diabetes mellitus, pregnancy, insulin, diabetic complications in pregnancy, diabetes management in pregnancy.

[1]
Diabetes Care and Research in Europe: The Saint Vincent declaration. Diabet Med 1990; 7(4): 360.
[http://dx.doi.org/10.1111/j.1464-5491.1990.tb01405.x] [PMID: 2140091]
[2]
World Health Organization (WHO). Global Report on Diabetes. 2016. Available from: https://www.who.int/publications/i/item/9789241565257
[3]
McCance DR, Casey C. Type 1 diabetes in pregnancy. Endocrinol Metab Clin North Am 2019; 48(3): 495-509.
[http://dx.doi.org/10.1016/j.ecl.2019.05.008] [PMID: 31345519]
[4]
Feldman AZ, Brown FM. Management of type 1 diabetes in pregnancy. Curr Diab Rep 2016; 16(8): 76.
[http://dx.doi.org/10.1007/s11892-016-0765-z] [PMID: 27337958]
[5]
Feig DS, Hwee J, Shah BR, Booth GL, Bierman AS, Lipscombe LL. Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: A large, population-based study in Ontario, Canada, 1996-2010. Diabetes Care 2014; 37(6): 1590-6.
[http://dx.doi.org/10.2337/dc13-2717] [PMID: 24705609]
[6]
Garne E, Loane M, Dolk H, et al. Spectrum of congenital anomalies in pregnancies with pregestational diabetes. Birth Defects Res A Clin Mol Teratol 2012; 94(3): 134-40.
[http://dx.doi.org/10.1002/bdra.22886] [PMID: 22371321]
[7]
Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care 2007; 30(7): 1920-5.
[http://dx.doi.org/10.2337/dc07-0278] [PMID: 17446531]
[8]
Confidential Enquiry into Maternal and Child Health. Pregnancy in women with type 1 and type 2 diabetes in 2002-03, England, Wales and Northern Ireland. London: CEMACH 2005.
[9]
Gutaj P, Zawiejska A, Wender-Ożegowska E, Brązert J. Maternal factors predictive of first-trimester pregnancy loss in women with pregestational diabetes. Pol Arch Med Wewn 2013; 123(1-2): 21-8.
[http://dx.doi.org/10.20452/pamw.1585] [PMID: 23302725]
[10]
Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester miscarriage-results from a UK-population-based case-control study. BJOG 2007; 114(2): 170-86.
[http://dx.doi.org/10.1111/j.1471-0528.2006.01193.x] [PMID: 17305901]
[11]
Casson IF, Clarke CA, Howard CV, et al. Outcomes of pregnancy in insulin dependent diabetic women: Results of a five year population cohort study. BMJ 1997; 315(7103): 275-8.
[http://dx.doi.org/10.1136/bmj.315.7103.275] [PMID: 9274545]
[12]
Mackin ST, Nelson SM, Kerssens JJ, et al. Diabetes and pregnancy: National trends over a 15 year period. Diabetologia 2018; 61(5): 1081-8.
[http://dx.doi.org/10.1007/s00125-017-4529-3] [PMID: 29322220]
[13]
Chaplin S. Latest findings from the National Pregnancy in Diabetes audit report. Pract Diabetes 2018; 35(1): 23-6.
[http://dx.doi.org/10.1002/pdi.2153]
[14]
Pedersen J. Diabetes and pregnancy; blood sugar of newborn infants during fasting and glucose administration. Ugeskr Laeger 1952; 114(21): 685.
[PMID: 14958933]
[15]
Teramo K, Kari MA, Eronen M, Markkanen H, Hiilesmaa V. High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in type 1 diabetic pregnancies. Diabetologia 2004; 47(10): 1695-703.
[http://dx.doi.org/10.1007/s00125-004-1515-3] [PMID: 15502930]
[16]
Mackin ST, Nelson SM, Wild SH, Colhoun HM, Wood R, Lindsay RS. Factors associated with stillbirth in women with diabetes. Diabetologia 2019; 62(10): 1938-47.
[http://dx.doi.org/10.1007/s00125-019-4943-9] [PMID: 31353418]
[17]
Ludvigsson JF, Neovius M, Söderling J, et al. Maternal glycemic control in type 1 diabetes and the risk for preterm birth: A Population-Based Cohort Study. Ann Intern Med 2019; 170(10): 691-701.
[http://dx.doi.org/10.7326/M18-1974] [PMID: 31009941]
[18]
Sibai BM, Caritis SN, Hauth JC, et al. Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies. The National institute of Child health and Human Development Maternal- Fetal Medicine Units Network. Am J Obstet Gynecol 2000; 183(6): 1520-4.
[http://dx.doi.org/10.1067/mob.2000.107621] [PMID: 11120521]
[19]
Murphy HR, Howgate C, O’Keefe J, et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: A 5-year national population-based cohort study. Lancet Diabetes Endocrinol 2021; 9(3): 153-64.
[http://dx.doi.org/10.1016/S2213-8587(20)30406-X] [PMID: 33516295]
[20]
Ballas J, Moore TR, Ramos GA. Management of diabetes in pregnancy. Curr Diab Rep 2012; 12(1): 33-42.
[http://dx.doi.org/10.1007/s11892-011-0249-0] [PMID: 22139557]
[21]
Sibai BM, Caritis S, Hauth J, et al. Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. Am J Obstet Gynecol 2000; 182(2): 364-9.
[http://dx.doi.org/10.1016/S0002-9378(00)70225-0] [PMID: 10694338]
[22]
Cohen AL, Wenger JB, James-Todd T, et al. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertens Pregnancy 2014; 33(1): 81-92.
[http://dx.doi.org/10.3109/10641955.2013.837175] [PMID: 24354578]
[23]
Temple RC, Aldridge V, Stanley K, Murphy HR. Glycaemic control throughout pregnancy and risk of pre-eclampsia in women with type I diabetes. BJOG 2006; 113(11): 1329-32.
[http://dx.doi.org/10.1111/j.1471-0528.2006.01071.x]
[24]
Haeri S, Khoury J, Kovilam O, Miodovnik M. The association of intrauterine growth abnormalities in women with type 1 diabetes mellitus complicated by vasculopathy. Am J Obstet Gynecol 2008; 199(3): 278.e1-5.
[http://dx.doi.org/10.1016/j.ajog.2008.06.066] [PMID: 18771982]
[25]
Cowett RM, Fox WW, Abman SH. Role of glucoregulatory hormones in hepatic glucose metabolism during the perinatal period A2 - Polin, Richard A Fetal and Neonatal Physiology. 3rd ed. W.B. Saunders 2004; pp. 478-86.
[26]
Demir Y, Taslimi P, Koçyiğit ÜM, et al. Determination of the inhibition profiles of pyrazolyl-thiazole derivatives against aldose reductase and α-glycosidase and molecular docking studies. Arch Pharm (Weinheim) 2020; 353(12): e2000118.
[http://dx.doi.org/10.1002/ardp.202000118] [PMID: 32761859]
[27]
Demir Y, Özaslan MS, Duran HE, Küfrevioğlu Öİ, Beydemir Ş. Inhibition effects of quinones on aldose reductase: Antidiabetic properties. Environ Toxicol Pharmacol 2019; 70: 103195.
[http://dx.doi.org/10.1016/j.etap.2019.103195] [PMID: 31125830]
[28]
Sever B, Altıntop MD, Demir Y, Akalın Çiftçi G, Beydemir Ş, Özdemir A. Design, synthesis, in vitro and in silico investigation of aldose reductase inhibitory effects of new thiazole-based compounds. Bioorg Chem 2020; 102: 104110.
[http://dx.doi.org/10.1016/j.bioorg.2020.104110] [PMID: 32739480]
[29]
Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care 2000; 23(8): 1084-91.
[http://dx.doi.org/10.2337/diacare.23.8.1084] [PMID: 10937502]
[30]
Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990; 13(1): 34-40.
[http://dx.doi.org/10.2337/diacare.13.1.34] [PMID: 2404715]
[31]
Morrison JL, Hodgson LA, Lim LL, Al-Qureshi S. Diabetic retinopathy in pregnancy: A review. Clin Exp Ophthalmol 2016; 44(4): 321-34.
[http://dx.doi.org/10.1111/ceo.12760] [PMID: 27062093]
[32]
Temple RC, Aldridge VA, Sampson MJ, Greenwood RH, Heyburn PJ, Glenn A. Impact of pregnancy on the progression of diabetic retinopathy in Type 1 diabetes. Diabet Med 2001; 18(7): 573-7.
[http://dx.doi.org/10.1046/j.1464-5491.2001.00535.x] [PMID: 11553188]
[33]
Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The diabetes in early pregnancy study. National institute of child health and human development diabetes in early pregnancy study. Diabetes Care 1995; 18(5): 631-7.
[http://dx.doi.org/10.2337/diacare.18.5.631] [PMID: 8586000]
[34]
Bourry J, Courteville H, Ramdane N, et al. Progression of diabetic retinopathy and predictors of its development and progression during pregnancy in patients with type 1 diabetes: A report of 499 pregnancies. Diabetes Care 2021; 44(1): 181-7.
[http://dx.doi.org/10.2337/dc20-0904] [PMID: 33177172]
[35]
National Institute for Health and Care Excellence (NICE). Diabetes in pregnancy: Management from preconception to the postnatal period [NG3]. 2015. Available from: nice.org.uk/guidance/ng3
[36]
Feig DS, Berger H, Donovan L, et al. Diabetes and Pregnancy. Can J Diabetes 2018; 42(1): S255-82.
[http://dx.doi.org/10.1016/j.jcjd.2017.10.038] [PMID: 29650105]
[37]
American Diabetes Association. 14. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44(1): S200-10.
[http://dx.doi.org/10.2337/dc21-S014] [PMID: 33298425]
[38]
Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013; 98(11): 4227-49.
[http://dx.doi.org/10.1210/jc.2013-2465] [PMID: 24194617]
[39]
Rudland VL, Price SAL, Hughes R, et al. ADIPS 2020 guideline for pre-existing diabetes and pregnancy. Aust N Z J Obstet Gynaecol 2020; 60(6): E18-52.
[http://dx.doi.org/10.1111/ajo.13265] [PMID: 33200400]
[40]
Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: Summary of evidence and consensus recommendations for care. Diabetes Care 2008; 31(5): 1060-79.
[http://dx.doi.org/10.2337/dc08-9020] [PMID: 18445730]
[41]
Rahman W, Rahman FZ, Yassin S, Al-Suleiman SA, Rahman J. Progression of retinopathy during pregnancy in type 1 diabetes mellitus. Clin Exp Ophthalmol 2007; 35(3): 231-6.
[http://dx.doi.org/10.1111/j.1442-9071.2006.01413.x] [PMID: 17430509]
[42]
Arun CS, Taylor R. Influence of pregnancy on long-term progression of retinopathy in patients with type 1 diabetes. Diabetologia 2008; 51(6): 1041-5.
[http://dx.doi.org/10.1007/s00125-008-0994-z] [PMID: 18392803]
[43]
Reece EA, Leguizamon G, Homko C. Pregnancy performance and outcomes associated with diabetic nephropathy. Am J Perinatol 1998; 15(7): 413-21.
[http://dx.doi.org/10.1055/s-2007-993968] [PMID: 9759908]
[44]
Rossing K, Jacobsen P, Hommel E, et al. Pregnancy and progression of diabetic nephropathy. Diabetologia 2002; 45(1): 36-41.
[http://dx.doi.org/10.1007/s125-002-8242-4] [PMID: 11845221]
[45]
Reece EA, Coustan DR, Hayslett JP, et al. Diabetic nephropathy: Pregnancy performance and fetomaternal outcome. Am J Obstet Gynecol 1988; 159(1): 56-66.
[http://dx.doi.org/10.1016/0002-9378(88)90494-2] [PMID: 3394754]
[46]
Bramham K. Diabetic nephropathy and pregnancy. Semin Nephrol 2017; 37(4): 362-9.
[http://dx.doi.org/10.1016/j.semnephrol.2017.05.008] [PMID: 28711075]
[47]
Purdy LP, Hantsch CE, Molitch ME, et al. Effect of pregnancy on renal function in patients with moderate-to-severe diabetic renal insufficiency. Diabetes Care 1996; 19(10): 1067-74.
[http://dx.doi.org/10.2337/diacare.19.10.1067] [PMID: 8886551]
[48]
Wilmot EG, Mansell P. Diabetes and pregnancy. Clin Med (Lond) 2014; 14(6): 677-80.
[http://dx.doi.org/10.7861/clinmedicine.14-6-677] [PMID: 25468858]
[49]
Sibai BM. Risk factors, pregnancy complications, and prevention of hypertensive disorders in women with pregravid diabetes mellitus. J Matern Fetal Med 2000; 9(1): 62-5.
[http://dx.doi.org/10.1002/(SICI)1520-6661(200001/02)9:1<62::AID-MFM13>3.0.CO;2-6] [PMID: 10757438]
[50]
Reece EA, Leguizamon G, Homko C. Stringent controls in diabetic nephropathy associated with optimization of pregnancy outcomes. J Matern Fetal Med 1998; 7(4): 213-6.
[http://dx.doi.org/10.1002/(SICI)1520-6661(199807/08)7:4<213::AID-MFM11>3.0.CO;2-E] [PMID: 9730491]
[51]
Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65(6): 1991-2002.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00620.x] [PMID: 15149313]
[52]
Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354(23): 2443-51.
[http://dx.doi.org/10.1056/NEJMoa055202] [PMID: 16760444]
[53]
Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: A systematic review. Hypertension 2012; 60(2): 444-50.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.196352] [PMID: 22753220]
[54]
Buschur EO, Polsky S. Type 1 diabetes: Management in women from preconception to postpartum. J Clin Endocrinol Metab 2021; 106(4): 952-67.
[http://dx.doi.org/10.1210/clinem/dgaa931] [PMID: 33331893]
[55]
Lee SI, Patel M, Jones CM, Narendran P. Cardiovascular disease and type 1 diabetes: Prevalence, prediction and management in an ageing population. Ther Adv Chronic Dis 2015; 6(6): 347-74.
[http://dx.doi.org/10.1177/2040622315598502] [PMID: 26568811]
[56]
Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ. Screening for coronary artery disease in patients with diabetes. Diabetes Care 2007; 30(10): 2729-36.
[http://dx.doi.org/10.2337/dc07-9927] [PMID: 17901530]
[57]
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643-53.
[http://dx.doi.org/10.1056/NEJMoa052187] [PMID: 16371630]
[58]
Bax JJ, Inzucchi SE, Bonow RO, Schuijf JD, Freeman MR, Barrett EJ. Cardiac imaging for risk stratification in diabetes. Diabetes Care 2007; 30(5): 1295-304.
[http://dx.doi.org/10.2337/dc06-2094] [PMID: 17259467]
[59]
Magee LA, von Dadelszen P, Bohun CM, et al. Serious perinatal complications of non-proteinuric hypertension: An international, multicentre, retrospective cohort study. J Obstet Gynaecol Can 2003; 25(5): 372-82.
[http://dx.doi.org/10.1016/S1701-2163(16)30579-5] [PMID: 12738978]
[60]
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507-20.
[http://dx.doi.org/10.1001/jama.2013.284427] [PMID: 24352797]
[61]
Türkeş C, Demir Y, Beydemir Ş. Anti-diabetic properties of calcium channel blockers: Inhibition effects on aldose reductase enzyme activity. Appl Biochem Biotechnol 2019; 189(1): 318-29.
[http://dx.doi.org/10.1007/s12010-019-03009-x] [PMID: 30980289]
[62]
Chaturvedi N, Fuller JH, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001; 24(12): 2071-7.
[http://dx.doi.org/10.2337/diacare.24.12.2071] [PMID: 11723085]
[63]
Napoli C, Glass CK, Witztum JL, Deutsch R, D’Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999; 354(9186): 1234-41.
[http://dx.doi.org/10.1016/S0140-6736(99)02131-5] [PMID: 10520631]
[64]
National Institute for Health and Care Excellence. Cardiovascular disease: Risk assessment and reduction, including lipid modification. 2014. Available from: nice.org.uk/guidance/cg181
[65]
Thorogood M, Seed M, De Mott K. Guideline Development G. Management of fertility in women with familial hypercholesterolaemia: Summary of NICE guidance. BJOG 2009; 116(4): 478-9.
[66]
Sibai BM, Viteri OA. Diabetic ketoacidosis in pregnancy. Obstet Gynecol 2014; 123(1): 167-78.
[http://dx.doi.org/10.1097/AOG.0000000000000060] [PMID: 24463678]
[67]
Mohan M, Baagar KAM, Lindow S. Management of diabetic ketoacidosis in pregnancy. Obstet Gynaecol 2017; 19(1): 55-62.
[http://dx.doi.org/10.1111/tog.12344]
[68]
Hawthorne G. Maternal complications in diabetic pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25(1): 77-90.
[http://dx.doi.org/10.1016/j.bpobgyn.2010.10.015] [PMID: 21130689]
[69]
Schneider MB, Umpierrez GE, Ramsey RD, Mabie WC, Bennett KA. Pregnancy complicated by diabetic ketoacidosis: Maternal and fetal outcomes. Diabetes Care 2003; 26(3): 958-9.
[http://dx.doi.org/10.2337/diacare.26.3.958] [PMID: 12610076]
[70]
Bryant SN, Herrera CL, Nelson DB, Cunningham FG. Diabetic ketoacidosis complicating pregnancy. J Neonatal Perinatal Med 2017; 10(1): 17-23.
[http://dx.doi.org/10.3233/NPM-1663] [PMID: 28304323]
[71]
Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013; 98(5): 1845-59.
[http://dx.doi.org/10.1210/jc.2012-4127] [PMID: 23589524]
[72]
Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER. Hypoglycemia in pregnant women with type 1 diabetes: Predictors and role of metabolic control. Diabetes Care 2008; 31(1): 9-14.
[http://dx.doi.org/10.2337/dc07-1066] [PMID: 17909091]
[73]
Jovanovic L, Knopp RH, Brown Z, et al. Declining insulin requirement in the late first trimester of diabetic pregnancy. Diabetes Care 2001; 24(7): 1130-6.
[http://dx.doi.org/10.2337/diacare.24.7.1130] [PMID: 11423491]
[74]
Kimmerle R, Heinemann L, Delecki A, Berger M. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type I diabetic women. Diabetes Care 1992; 15(8): 1034-7.
[http://dx.doi.org/10.2337/diacare.15.8.1034] [PMID: 1505305]
[75]
Björklund AO, Adamson UK, Almström NH, et al. Effects of hypoglycaemia on fetal heart activity and umbilical artery Doppler velocity waveforms in pregnant women with insulin-dependent diabetes mellitus. Br J Obstet Gynaecol 1996; 103(5): 413-20.
[http://dx.doi.org/10.1111/j.1471-0528.1996.tb09766.x] [PMID: 8624313]
[76]
Zisser HC, Biersmith MA, Jovanovič LB, Yogev Y, Hod M, Kovatchev BP. Fetal risk assessment in pregnancies complicated by diabetes mellitus. J Diabetes Sci Technol 2010; 4(6): 1368-73.
[http://dx.doi.org/10.1177/193229681000400610] [PMID: 21129331]
[77]
Wahabi HA, Alzeidan RA, Bawazeer GA, Alansari LA, Esmaeil SA. Preconception care for diabetic women for improving maternal and fetal outcomes: A systematic review and meta-analysis. BMC Pregnancy Childbirth 2010; 10: 63.
[http://dx.doi.org/10.1186/1471-2393-10-63] [PMID: 20946676]
[78]
Macintosh MC, Fleming KM, Bailey JA, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: Population based study. BMJ 2006; 333(7560): 177.
[http://dx.doi.org/10.1136/bmj.38856.692986.AE] [PMID: 16782722]
[79]
Chung JH, Melsop KA, Gilbert WM, Caughey AB, Walker CK, Main EK. Increasing pre-pregnancy body mass index is predictive of a progressive escalation in adverse pregnancy outcomes. J Matern Fetal Neonatal Med 2012; 25(9): 1635-9.
[http://dx.doi.org/10.3109/14767058.2011.648970] [PMID: 22185383]
[80]
Cnattingius S, Bergström R, Lipworth L, Kramer MS. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med 1998; 338(3): 147-52.
[http://dx.doi.org/10.1056/NEJM199801153380302] [PMID: 9428815]
[81]
Singh S, McGlennan A, England A, Simons R. A validation study of the CEMACH recommended modified early obstetric warning system (MEOWS). Anaesthesia 2012; 67(1): 12-8.
[http://dx.doi.org/10.1111/j.1365-2044.2011.06896.x] [PMID: 22066604]
[82]
Zhanel GG, Nicolle LE, Harding GK. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. Clin Infect Dis 1995; 21(2): 316-22.
[http://dx.doi.org/10.1093/clinids/21.2.316] [PMID: 8562738]
[83]
National Guideline Alliance (Great Britain). Hypertension in pregnancy: Diagnosis and management. UK: National Institute for Health and Care Excellence 2019. Available from: https://www.nice.org.uk/guidance/ng133
[84]
Gurram P, Benn P, Campbell WA. Impact of diabetes on aneuploidy screening. Clin Lab Med 2013; 33(2): 271-80.
[http://dx.doi.org/10.1016/j.cll.2013.03.022] [PMID: 23702117]
[85]
ACOG Committee on Practice Bulletins. Pregestational diabetes mellitus. Obstet Gynecol 2005; 105(3): 675-85.
[http://dx.doi.org/10.1097/00006250-200503000-00049] [PMID: 15738045]
[86]
Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 2009; 32(6): 1046-8.
[http://dx.doi.org/10.2337/dc08-2061] [PMID: 19265024]
[87]
Ludvigsson JF, Neovius M, Söderling J, et al. Periconception glycaemic control in women with type 1 diabetes and risk of major birth defects: population based cohort study in Sweden. BMJ 2018; 362: k2638.
[http://dx.doi.org/10.1136/bmj.k2638] [PMID: 29976596]
[88]
Eriksen NB, Damm P, Mathiesen ER, Ringholm L. The prevalence of congenital malformations is still higher in pregnant women with pregestational diabetes despite near-normal HbA1c: A literature review. J Matern Fetal Neonatal Med 2019; 32(8): 1225-9.
[http://dx.doi.org/10.1080/14767058.2017.1402880] [PMID: 29172827]
[89]
Ilic S, Jovanovic L, Wollitzer AO. Is the paradoxical first trimester drop in insulin requirement due to an increase in C-peptide concentration in pregnant type I diabetic women? Diabetologia 2000; 43(10): 1329-30.
[http://dx.doi.org/10.1007/s001250051530] [PMID: 11079753]
[90]
Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: How using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 2017; 40(8): 994-9.
[http://dx.doi.org/10.2337/dc17-0636] [PMID: 28733374]
[91]
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care 2019; 42(8): 1593-603.
[http://dx.doi.org/10.2337/dci19-0028] [PMID: 31177185]
[92]
Murphy HR, Rayman G, Duffield K, et al. Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy. Diabetes Care 2007; 30(11): 2785-91.
[http://dx.doi.org/10.2337/dc07-0500] [PMID: 17666464]
[93]
Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): A multicentre international randomised controlled trial. Lancet 2017; 390(10110): 2347-59.
[http://dx.doi.org/10.1016/S0140-6736(17)32400-5] [PMID: 28923465]
[94]
Kristensen K, Ögge LE, Sengpiel V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: An observational cohort study of 186 pregnancies. Diabetologia 2019; 62(7): 1143-53.
[http://dx.doi.org/10.1007/s00125-019-4850-0] [PMID: 30904938]
[95]
Nørgaard K, Sukumar N, Rafnsson SB, Saravanan P. Efficacy and safety of rapid-acting insulin analogs in special populations with type 1 diabetes or gestational diabetes: Systematic review and meta-analysis. Diabetes Ther 2018; 9(3): 891-917.
[http://dx.doi.org/10.1007/s13300-018-0411-7] [PMID: 29623593]
[96]
European Medicines Agency. Summary of Product Characteristics. Fiasp: EPAR - Medicine overview. 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/fiasp-eparproduct-information_en.pdf
[97]
Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30(4): 771-6.
[http://dx.doi.org/10.2337/dc06-1887] [PMID: 17392539]
[98]
U.S Food and Drug Administration. Product Information - Fiasp (insulin aspart). 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208751s000lbl.pdf
[99]
A randomised controlled trial comparing the effect of the faster-acting insulin analog - insulin fiasp® - versus insulin novorapid® in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03770767
[100]
Lepercq J, Lin J, Hall GC, et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int 2012; 2012: 649070.
[http://dx.doi.org/10.1155/2012/649070] [PMID: 22685467]
[101]
Keller MF, Vestgaard M, Damm P, Mathiesen ER, Ringholm L. Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: An observational study of 22 cases. Diabetes Res Clin Pract 2019; 152: 58-64.
[http://dx.doi.org/10.1016/j.diabres.2019.05.004] [PMID: 31102682]
[102]
Bonora BM, Avogaro A, Fadini GP. Exposure to insulin degludec during pregnancy: Report of a small series and review of the literature. J Endocrinol Invest 2019; 42(3): 345-9.
[http://dx.doi.org/10.1007/s40618-018-0926-9] [PMID: 30043095]
[103]
A trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes. 2020. Available from: clinicaltrials.gov/ct2/show/NCT03377699
[104]
Rys PM, Ludwig-Slomczynska AH, Cyganek K, Malecki MT. Continuous subcutaneous insulin infusion vs. multiple daily injections in pregnant women with type 1 diabetes mellitus: A systematic review and meta-analysis of randomised controlled trials and observational studies. Eur J Endocrinol 2018; 178(5): 545-63.
[http://dx.doi.org/10.1530/EJE-17-0804] [PMID: 29545258]
[105]
Farrar D, Tuffnell DJ, West J, West HM. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2016; (6): CD005542.
[http://dx.doi.org/10.1002/14651858.CD005542.pub3] [PMID: 27272351]
[106]
Ranasinghe PD, Maruthur NM, Nicholson WK, et al. Comparative effectiveness of continuous subcutaneous insulin infusion using insulin analogs and multiple daily injections in pregnant women with diabetes mellitus: A systematic review and meta-analysis. J Womens Health (Larchmt) 2015; 24(3): 237-49.
[http://dx.doi.org/10.1089/jwh.2014.4939] [PMID: 25713996]
[107]
Jotic A, Milicic T, Lalic K, et al. Evaluation of glycaemic control, glucose variability and hypoglycaemia on long-term continuous subcutaneous infusion vs. multiple daily injections: Observational study in pregnancies with pre-existing type 1 diabetes. Diabetes Ther 2020; 11(4): 845-58.
[http://dx.doi.org/10.1007/s13300-020-00780-7] [PMID: 32060738]
[108]
Feig DS, Corcoy R, Donovan LE, et al. Pumps or multiple daily injections in pregnancy involving type 1 diabetes: A prespecified analysis of the CONCEPTT randomized trial. Diabetes Care 2018; 41(12): 2471-9.
[http://dx.doi.org/10.2337/dc18-1437] [PMID: 30327362]
[109]
Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: Patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev 2016; 32(1): 21-39.
[http://dx.doi.org/10.1002/dmrr.2653] [PMID: 25865292]
[110]
White SL, Brackenridge A, Rajasingam D. Insulin pumps and pregnancy. Obstet Gynaecol 2016; 18(3): 199-203.
[http://dx.doi.org/10.1111/tog.12268]
[111]
Stewart ZA, Wilinska ME, Hartnell S, et al. Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: A randomized controlled crossover trial. Diabetes Care 2018; 41(7): 1391-9.
[http://dx.doi.org/10.2337/dc17-2534] [PMID: 29535135]
[112]
Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: Meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343: d3805.
[http://dx.doi.org/10.1136/bmj.d3805] [PMID: 21737469]
[113]
Yu Q, Aris IM, Tan KH, Li LJ. Application and utility of continuous glucose monitoring in pregnancy: A systematic review. Front Endocrinol (Lausanne) 2019; 10: 697.
[http://dx.doi.org/10.3389/fendo.2019.00697] [PMID: 31681170]
[114]
Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER. The effect of real-time continuous glucose monitoring in pregnant women with diabetes: A randomized controlled trial. Diabetes Care 2013; 36(7): 1877-83.
[http://dx.doi.org/10.2337/dc12-2360] [PMID: 23349548]
[115]
Pryde PG, Besinger RE, Gianopoulos JG, Mittendorf R. Adverse and beneficial effects of tocolytic therapy. Semin Perinatol 2001; 25(5): 316-40.
[http://dx.doi.org/10.1053/sper.2001.27547] [PMID: 11707019]
[116]
Dashora U, Murphy HR, Temple RC, et al. Managing hyperglycaemia during antenatal steroid administration, labour and birth in pregnant women with diabetes. Diabet Med 2018; 35(8): 1005-10.
[http://dx.doi.org/10.1111/dme.13674] [PMID: 30152588]
[117]
Bartholomew ML, Soules K, Church K, et al. Managing diabetes in pregnancy using cell phone/internet technology. Clin Diabetes 2015; 33(4): 169-74.
[http://dx.doi.org/10.2337/diaclin.33.4.169] [PMID: 26487790]
[118]
Kennelly MA, Ainscough K, Lindsay K, Gibney E, Mc Carthy M, McAuliffe FM. Pregnancy, exercise and nutrition research study with smart phone app support (Pears): Study protocol of a randomized controlled trial. Contemp Clin Trials 2016; 46: 92-9.
[http://dx.doi.org/10.1016/j.cct.2015.11.018] [PMID: 26625980]
[119]
Ming WK, Mackillop LH, Farmer AJ, et al. Telemedicine technologies for diabetes in pregnancy: A systematic review and meta- analysis. J Med Internet Res 2016; 18(11): e290.
[http://dx.doi.org/10.2196/jmir.6556] [PMID: 27829574]
[120]
Linden K, Berg M, Adolfsson A, Sparud-Lundin C. Person-centred, web-based support in pregnancy and early motherhood for women with type 1 diabetes mellitus: A randomized controlled trial. Diabet Med 2018; 35(2): 232-41.
[http://dx.doi.org/10.1111/dme.13552] [PMID: 29171071]
[121]
Jovanovic L. Glucose and insulin requirements during labor and delivery: The case for normoglycemia in pregnancies complicated by diabetes. Endocr Pract 2004; 10(2): 40-5.
[http://dx.doi.org/10.4158/EP.10.S2.40] [PMID: 15251639]
[122]
Barrett HL, Morris J, McElduff A. Watchful waiting: A management protocol for maternal glycaemia in the peripartum period. Aust N Z J Obstet Gynaecol 2009; 49(2): 162-7.
[http://dx.doi.org/10.1111/j.1479-828X.2009.00969.x] [PMID: 19432604]
[123]
American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37: 14-80.
[http://dx.doi.org/10.2337/dc14-S014]
[124]
Kalra P, Anakal M. Peripartum management of diabetes. Indian J Endocrinol Metab 2013; S72-6.
[http://dx.doi.org/10.4103/2230-8210.119510]
[125]
Drever E, Tomlinson G, Bai AD, Feig DS. Insulin pump use compared with intravenous insulin during labour and delivery: The INSPIRED observational cohort study. Diabet Med 2016; 33(9): 1253-9.
[http://dx.doi.org/10.1111/dme.13106] [PMID: 26927202]
[126]
Gabbe SG, Carpenter LB, Garrison EA. New strategies for glucose control in patients with type 1 and type 2 diabetes mellitus in pregnancy. Clin Obstet Gynecol 2007; 50(4): 1014-24.
[http://dx.doi.org/10.1097/GRF.0b013e31815a6435] [PMID: 17982345]
[127]
Riviello C, Mello G, Jovanovic LG. Breastfeeding and the basal insulin requirement in type 1 diabetic women. Endocr Pract 2009; 15(3): 187-93.
[http://dx.doi.org/10.4158/EP.15.3.187] [PMID: 19364685]
[128]
Schoen S, Sichert-Hellert W, Hummel S, Ziegler AG, Kersting M. Breastfeeding duration in families with type 1 diabetes compared to non-affected families: Results from BABYDIAB and DONALD studies in Germany. Breastfeed Med 2008; 3(3): 171-5.
[http://dx.doi.org/10.1089/bfm.2007.0027] [PMID: 18778212]
[129]
Hummel S, Winkler C, Schoen S, et al. Breastfeeding habits in families with type 1 diabetes. Diabet Med 2007; 24(6): 671-6.
[http://dx.doi.org/10.1111/j.1464-5491.2007.02148.x] [PMID: 17403118]
[130]
Hartmann P, Cregan M. Lactogenesis and the effects of insulin-dependent diabetes mellitus and prematurity. J Nutr 2001; 131(11): 3016S-20S.
[http://dx.doi.org/10.1093/jn/131.11.3016S] [PMID: 11694639]
[131]
Cordero L, Ramesh S, Hillier K, Giannone PJ, Nankervis CA. Early feeding and neonatal hypoglycemia in infants of diabetic mothers. SAGE Open Med 2013; 1: 2050312113516613.
[http://dx.doi.org/10.1177/2050312113516613] [PMID: 26770697]
[132]
Al Mamun A, O’Callaghan MJ, Williams GM, Najman JM, Callaway L, McIntyre HD. Breastfeeding is protective to diabetes risk in young adults: A longitudinal study. Acta Diabetol 2015; 52(5): 837-44.
[http://dx.doi.org/10.1007/s00592-014-0690-z] [PMID: 25539880]

Rights & Permissions Print Cite
Article Metrics
90
1
© 2024 Bentham Science Publishers | Privacy Policy